Hans Keirstead

Chairman, Immunis

“I think that the data for cardiovascular health from GLP-1s as a result of fat reduction, diet alteration, and betterment of plaque in the cardiovascular system is probably where this is going to have its greatest effect.”

Lindsay Holden

Co-founder & COO, Baseline Therapeutics

“Beyond weight loss, GLP-1s may have their most disruptive impact in substance use disorder. These therapies have shown promising effects in reducing drug and alcohol use in Phase 2 and EHR studies.

Today, Baseline Therapeutics and Eli Lilly are both advancing phase 3 programmes with GLP-1RAs for alcohol use disorder. If successful, this will represent a major breakthrough for addiction medicine, with the potential to dramatically improve the health and well-being of the nearly 29 million Americans living with alcohol use disorder and their families.

The adoption of GLP-1 treatments for alcohol use will be driven not just by superior efficacy, but also the broadly beneficial attributes of this drug class, which are highly appealing to both patients and prescribers.”

Jamie Coleman

Chief Commercial Officer, Kailera

“GLP-1 therapies have transformed obesity care, yet global adoption remains in the single digits – showing just how undertreated this chronic disease still is. And for the nearly half of US adults with obesity projected to have a BMI over 35, today’s treatments often aren’t enough to achieve the level of weight loss they need.

With these realities in mind, Kailera is advancing a diversified pipeline of oral and injectable GLP-1–based therapies designed to address critical care gaps and meet people where they are in their treatment journey.”

Dr Beverly Tchang

Associate Professor of Clinical Medicine, Weill Cornell

“If we had a ministry of happiness and a happiness index, it would be off the charts. So many patients have told me how they're able to be more present with friends and family, now that food and weight are no longer issues, and I think this repair of social connections is what has been the most impactful and most needed."

Geoff Cook

CEO, Noom

"A major pharmaceutical company’s chief scientific officer called GLP-1s “proven longevity medicine” at a major conference last year in Copenhagen. We will see GLP-1s disrupt the supplement industry as they become the entry point for prescription-grade wellness.

The evidence for GLP-1 improving inflammation, knee pain, addiction, and cardiovascular disease will continue to mount. Pharmaceutical companies will begin to engineer pipelines to support prescription-grade wellness and cash-pay proactive care markets."

Leslie Oley Wilberforce

CEO, Evidation

"Beyond weight loss, over the next year, GLP-1s are accelerating two fundamental shifts in healthcare: the scaling of direct-to-consumer care models and a more integrated approach to managing chronic disease.

On the direct-to-consumer side, over the next year, the demand for these therapies, combined with competition and access constraints in traditional channels, is shifting more control to consumers. People are increasingly shaping where they access care, how therapies are used, and what level of ongoing support they expect.

At the same time, we’ll see obesity function more clearly as an entry point to managing multiple conditions across the whole person. That convergence raises expectations for coordinated, longitudinal support and begins to challenge disease-by-disease care models, even if broader system redesign takes longer to unfold."

Laurent Audoly

CEO, Prive Bio

"For general obesity-related comorbidities, one can think about different things like sleep apnoea as one example. Kidney disease is another example, cardiovascular diseases as yet another opportunity. So, I think what we've seen, and what we'll will keep on seeing, is that the opportunities to really get your metabolic dysfunction and obesity under control will have deep ramifications.

Now, on the flip side, compliance is still a problem. I mean, I think we're seeing a lot of data here that tells us that somebody that starts on GLP-1s today certainly might not be on a GLP-1 in one year, not because they're done with it, but just because there's all sorts of opportunities and challenges that have come up for that particular individual."